Cellceuti, a clinical-stage
biopharm company developing therapies in oncology, dermatology, and antibiotic
applications, reports that the U.S. Food and Drug Administration’s (FDA) 30-day
waiting period pertaining to the company’s Investigational New Drug Application
(“IND”) for Prurisol™ has now passed and that the company is moving toward the
commencement of clinical trials of the drug candidate for the treatment of
psoriasis.
“This is another significant
moment for our company as we bring our third compound into clinical trials,”
Cellceutix CEO Leo Ehrlich stated in the news release. “A steady stream of
developments has led to a great start to 2014 for our company. We initiated a
multi-center phase 2b trial of our novel antibiotic Brilacidin. The phase 1
trial of our novel anti-cancer compound Kevetrin™ is in the seventh cohort and
now Prurisol™ is set to enter human trials, positioning us with three clinical
drug candidates targeting three different areas of unmet medical need.”
Ehrlich further explained
the company’s research to expand Brilacidin for a wide range of indications.
“We are nearing completion
of IND-enabling studies of Brilacidin-OM for oral mucositis. Other pre-clinical
studies of Brilacidin are ongoing for otitis and ophthalmic infections,” he
stated. “Separately, in our recent acquisition of assets we acquired a library
of compounds that have shown promise for Gram-negative bacterial infections.
These compounds have been sent to a university laboratory in Texas for further
testing. We are actively developing other acquired compounds for anti-fungal
treatments. In short, while we are very pleased with the clinical development
to date, we feel that there are many other areas of tremendous opportunity for
our pipeline and intend to relentlessly research them to define future clinical
trials.”
Cellceutix is developing
Prurisol under FDA guidance that a 505(b)(2) designation is an appropriate
development pathway. Upon successful completion of the crossover trial to
demonstrate that Prurisol converts to abacavir in humans, the company plans to
initiate a larger phase 2/3 clinical trial under a 505(b)(2) designation, which
would permit Prurisol to move to advanced trials.
Cellceutix previously
submitted to the FDA an application for an Orphan Drug designation for
Brilacidin-OM for the prevention of oral mucositis in head and neck cancer
patients. Following its review, the agency advised the company that the data
would indicate that Brilacidin-OM could treat a patient population that is
actually too large for an Orphan Drug designation. The company said it may
narrow the focus of the application and continue the dialogue with the FDA
going forward or pursue the larger market.
For more information visit
www.cellceutix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
